| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7ec54e77f01fbfd3703ae971ad32e8c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
| filingDate |
2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce8c7b58194969734b37cfc0a250e7d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2b2b773a4aa202ebd9883d56c3c256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_875a1b9a79c4d4b50151c1bd758bc811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94b25c703993d451051f6338da311e3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_930dfe5b5f8c15661208a5df080f43ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88b62f7795b5f005e81ae664b134e63a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d9686b0e1302761add113f8cc900ff0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec4f17312b38087b91593d0655dcf376 |
| publicationDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2740754-C1 |
| titleOfInvention |
Pharmaceutical composition of neuroprotective action for oral administration based on hexamethylene amide bis-(n-monosuccinyl-1-glutamyl-l-lysine) (versions), made in form of a tablet dispersible in the oral cavity |
| abstract |
FIELD: medicine; pharmacy. n SUBSTANCE: invention relates to pharmaceutical compositions having neuroprotective activity in the form of a tablet, dispersed in the oral cavity containing hexamethylene amide bis-(N-monosuccinyl-L-glutamyl-L-lysine) as an active substance. Effect of the composition is shown on the model of haloperidol catalepsy. Suggested tablets meet the requirements of State Pharmacopeia XIII. n EFFECT: technical result of the invention is higher efficiency of using hexamethylene amide bis-(N-monosuccinyl-L-glutamyl-L-lysine) by creating pharmaceutical compositions, having neuroprotective action; wider range of neuroprotective agents dispersed in the oral cavity. n 15 cl, 11 ex, 3 tbl, 1 dwg |
| priorityDate |
2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |